| RS2102735278 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Alpha-actinopathy |
| RS2102735477 |
H3-3A
|
Health Risk |
Likely pathogenic |
— |
| RS2102735576 |
H3-3A
|
Health Risk |
Pathogenic |
Bryant-Li-Bhoj neurodevelopmental syndrome 1, Bryant-Li-Bhoj neurodevelopmental syndrome 1 |
| RS2102735630 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102735801 |
H3-3A
|
Health Risk |
Pathogenic/Likely pathogenic |
Brain imaging abnormality, Delayed speech and language development |
| RS2102735854 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102735904 |
ACTA1
|
Health Risk |
Likely pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102735931 |
ACTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2102735950 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102735965 |
ACTA1
|
Health Risk |
Pathogenic |
— |
| RS2102736194 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102736219 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102736312 |
ACTA1
|
Health Risk |
Likely pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102736333 |
COG2
|
Health Risk |
Likely pathogenic |
See cases, See cases |
| RS2102736351 |
ACTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2102736408 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102736416 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102736554 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Congenital myopathy 2c |
| RS2102736562 |
ACTA1
|
Health Risk |
Pathogenic |
Actin accumulation myopathy, Actin accumulation myopathy |
| RS2102736976 |
H3-3A
|
Health Risk |
Likely pathogenic |
Intellectual disability, Global developmental delay |
| RS2102741149 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS2102741288 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102741367 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS2102741708 |
GALNT2
|
Health Risk |
Likely pathogenic |
Congenital disorder of glycosylation, type iit |
| RS2102742278 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102742543 |
H3-3A
|
Health Risk |
Pathogenic |
— |
| RS2102742562 |
H3-3A
|
Health Risk |
Pathogenic |
Global developmental delay, Intellectual disability |
| RS2102748161 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102760660 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102762663 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102763350 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102763351 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome type 2A, Usher syndrome type 2A |
| RS2102763421 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102766786 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102766834 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102766886 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102767109 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102769946 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102769969 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102770892 |
CACNA1E
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Inborn genetic diseases |
| RS2102772927 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102773181 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102773374 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102778169 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102778466 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS2102778595 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102778597 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS2102778615 |
USH2A
|
Health Risk |
Pathogenic |
Usher syndrome type 2A, Retinitis pigmentosa 39 |
| RS2102778641 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102778824 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS2102778849 |
SERPINC1
|
Health Risk |
Likely pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102778876 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102778910 |
SERPINC1
|
Health Risk |
Likely pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102780481 |
B3GALNT2
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a |
| RS2102782435 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102783199 |
SERPINC1
|
Health Risk |
Likely pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102783738 |
USH2A
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 39, Retinitis pigmentosa 39 |
| RS2102783758 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102783934 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102784614 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102784860 |
B3GALNT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a |
| RS2102785788 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102786101 |
SERPINC1
|
Health Risk |
Likely pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102788200 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102788229 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102788650 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102788658 |
USH2A
|
Health Risk |
Likely pathogenic |
Retinitis pigmentosa 39, Retinitis pigmentosa 39 |
| RS2102788720 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS2102788764 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102788868 |
USH2A
|
Health Risk |
Likely pathogenic |
Usher syndrome type 2A, Retinal dystrophy |
| RS2102788946 |
USH2A
|
Health Risk |
Pathogenic |
Usher syndrome type 2A, Usher syndrome type 2A |
| RS2102789194 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Retinitis pigmentosa 39, Retinitis pigmentosa 39 |
| RS2102789590 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102789885 |
SERPINC1
|
Health Risk |
Pathogenic |
Hereditary antithrombin deficiency, Hereditary antithrombin deficiency |
| RS2102790139 |
B3GALNT2
|
Health Risk |
Conflicting classifications of pathogenicity |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a |
| RS2102791328 |
AGT
|
Health Risk |
Likely pathogenic |
Anhydramnios, Large fontanelles |
| RS2102792992 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome type 2A, Usher syndrome type 2A |
| RS2102792994 |
USH2A
|
Health Risk |
Likely pathogenic |
Usher syndrome type 2A, USH2A-related disorder |
| RS2102793202 |
USH2A
|
Health Risk |
Pathogenic |
Usher syndrome type 2, Usher syndrome type 2 |
| RS2102796345 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome type 2A, Usher syndrome type 2A |
| RS2102796365 |
USH2A
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 39, Retinitis pigmentosa 39 |
| RS2102796376 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102796387 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102796411 |
USH2A
|
Health Risk |
Pathogenic |
Usher syndrome type 2A, Usher syndrome type 2A |
| RS2102796431 |
CACNA1E
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2102796558 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa 39 |
| RS2102813310 |
GNPAT
|
Health Risk |
Pathogenic |
— |
| RS2102813590 |
PAPPA2
|
Health Risk |
Pathogenic |
Short stature, Dauber-Argente type |
| RS2102814284 |
IARS2
|
Health Risk |
Likely pathogenic |
— |
| RS2102815215 |
B3GALNT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a |
| RS2102815577 |
B3GALNT2
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a |
| RS2102816598 |
USH2A
|
Health Risk |
Pathogenic |
— |
| RS2102816719 |
LMNA
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Cardiovascular phenotype |
| RS2102817088 |
LMNA
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2102817265 |
LMNA
|
Health Risk |
Pathogenic |
— |
| RS2102817550 |
LMNA
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2102817644 |
LMNA
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2102817667 |
LMNA
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2102817698 |
LMNA
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2102817930 |
LMNA
|
Health Risk |
Likely pathogenic |
Hutchinson-Gilford syndrome, Hutchinson-Gilford syndrome |